Phathom Pharmaceuticals stock analysis
Want to see PHAT full AI Analyst Report?
Phathom Pharmaceuticals (PHAT) Stock Price & Analysis
PHAT Stock Chart & Stats
- Day’s Range
- $4.62 - $5.15
- 52-Week Range
- $4.62 - $18.31
- Previous Close
- $5.08
- Volume
- N/A
- Average Volume (3M)
- 1.69M
- Market Cap
- $412.96M
- Enterprise Value
- $990.61M
- Total Cash (Recent Filing)
- $184.56M
- Total Debt (Recent Filing)
- $167.96M
- Price to Earnings (P/E)
- ―
- Beta
- 2.16
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- -0.09
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And Improving Operating Profitability
Strong revenue growth combined with consecutive operating profitability indicates that VOQUEZNA is gaining commercial traction and that fixed commercial costs may be increasingly leveraged. If this pattern persists, improving scale could support a more durable transition toward profitability and internally funded growth.
Growing Prescription Base And Broad Payer Coverage
A large and expanding prescription base provides evidence of sustained product adoption rather than reliance on a small initial customer group. Broad commercial coverage can reduce reimbursement barriers, support continued physician prescribing, and improve the franchise’s ability to compound revenue over the next several quarters.
Cash Position Supports Continued Commercial Investment
Cash materially above the financing covenant gives Phathom room to continue commercializing VOQUEZNA and fund development activities without an immediate need for another debt or equity raise. That flexibility is important while management works toward durable positive cash flow in 2027.
Bears Say
Persistent Net Losses And Negative Cash Generation
Despite strong product-level gross margins and improving quarterly results, Phathom remains meaningfully unprofitable and cash-flow negative on a trailing basis. Continued losses consume financial resources, making the planned 2027 cash-flow inflection important and leaving execution dependent on sustaining revenue growth and expense discipline.
Deeply Negative Shareholder Equity
Deeply negative equity reflects the cumulative impact of prior losses and limits balance-sheet flexibility even though latest reported debt was low. This capital structure leaves less capacity to absorb setbacks, increases dependence on successful commercialization, and could constrain future financing and capital-allocation choices.
Regulatory Litigation Threatens Exclusivity Visibility
The litigation creates uncertainty around the timing and durability of VOQUEZNA’s asserted protection through May 3, 2032. An adverse regulatory or legal outcome could accelerate generic competition, weaken future revenue visibility, and reduce the commercial value of Phathom’s primary product franchise.
Phathom Pharmaceuticals News
Cantor sees low odds of suit leading FDA to reverse on Phathom exclusivity
After Phathom Pharmaceuticals (PHAT) announced that BDR Pharmaceuticals filed a suit against the FDA, challenging the agency’s refusal to receive an abbreviated new drug application that referenced Phathom’s new drug
Phathom Pharmaceuticals gives update on litigation filed by BDR Pharmaceuticals
Phathom Pharmaceuticals (PHAT) announced that BDR Pharmaceuticals has filed suit against the FDA and related Federal Defendants in the United States District Court for the District of Columbia, principally challenging
PHAT FAQ
What was Phathom Pharmaceuticals’s price range in the past 12 months?
What is Phathom Pharmaceuticals’s market cap?
When is Phathom Pharmaceuticals’s upcoming earnings report date?
How were Phathom Pharmaceuticals’s earnings last quarter?
Is Phathom Pharmaceuticals overvalued?
Does Phathom Pharmaceuticals pay dividends?
What is Phathom Pharmaceuticals’s EPS estimate?
How many shares outstanding does Phathom Pharmaceuticals have?
What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Phathom Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Phathom Pharmaceuticals Stock Smart Score
Company Description
Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven L. Basta
- Employees
- 371
- Website
- www.phathompharma.com
- Address
- 100 Campus Drive, Florham Park, NJ, 07932, US
Phathom Pharmaceuticals (PHAT) Earnings & Revenues
PHAT Company Deck
PHAT Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, supported by 71% year-over-year revenue growth, 14% sequential growth, a second consecutive quarter of operating profitability, positive operating cash flow, more than two million prescriptions filled, reaffirmed full-year guidance, and a substantial cash balance. The main challenges were a Q3 gross margin miss, expected higher Q4 gross-to-net discount, gradual access adoption, and litigation concerning VOQUEZNA's exclusivity, but management remained confident in the commercial trajectory, cash outlook, development pipeline, and long-term GI strategy.
View all PHAT earnings summariesPHAT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 2 | 15 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 0 | 0 | 12 |













